Abliva - Termination of coverage
Edison Investment Research is terminating coverage on Abliva (ABLI). Please note you should no longer rely on any previous research or estimates...
181 Views
Abliva - Termination of coverage
Edison Investment Research is terminating coverage on Doctor Care Anywhere (DOC), Argentex Group (AGFX), Newmont Corporation (NEM), GB Group (GBG),...
669 Views
Abliva - KL1333 ready for pivotal Phase II/III trial
Just a few months in, Abliva’s new CEO has already spearheaded a successful private placement (SEK80m gross in March 2021), which will now support...
554 Views
Abliva - New strategic investor on board and CMD
The rights issue announced on 19 February 2020 is now complete with 90% of the total amount of offered shares subscribed raising a total SEK67m. A...
137 Views
NeuroVive Pharmaceutical - Rights issue and focus on core assets
In February 2020, NeuroVive announced a rights issue (subject to EGM approval) aiming to raise up to SEK74m gross at a price of SEK0.80 per share,...
674 Views